PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.34%
Revenue growth of 2.34% while 1177.HK is flat. Bruce Berkowitz would check if a small edge can widen further.
24.74%
Gross profit growth of 24.74% while 1177.HK is zero. Bruce Berkowitz would see if minimal improvements could expand further.
84.81%
EBIT growth of 84.81% while 1177.HK is zero. Bruce Berkowitz would see if small gains can be scaled further.
2295.40%
Operating income growth of 2295.40% while 1177.HK is zero. Bruce Berkowitz would see if this modest edge can become significant.
-42.74%
Negative net income growth while 1177.HK stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-57.93%
Negative EPS growth while 1177.HK is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-61.49%
Negative diluted EPS growth while 1177.HK is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-7.85%
Share reduction while 1177.HK is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-8.69%
Reduced diluted shares while 1177.HK is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-34.14%
Negative OCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-100.00%
Negative FCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
3551.69%
10Y revenue/share CAGR above 1.5x 1177.HK's 137.22%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
146.88%
5Y revenue/share CAGR above 1.5x 1177.HK's 42.57%. David Dodd would look for consistent product or market expansions fueling outperformance.
34.91%
3Y revenue/share CAGR 1.25-1.5x 1177.HK's 23.57%. Bruce Berkowitz might see better product or regional expansions than the competitor.
177.47%
Positive long-term OCF/share growth while 1177.HK is negative. John Neff would see a structural advantage in sustained cash generation.
280.14%
OCF/share CAGR of 280.14% while 1177.HK is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-37.54%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
93.29%
Positive 10Y CAGR while 1177.HK is negative. John Neff might see a substantial advantage in bottom-line trajectory.
70.78%
Positive 5Y CAGR while 1177.HK is negative. John Neff might view this as a strong mid-term relative advantage.
45.80%
Positive short-term CAGR while 1177.HK is negative. John Neff would see a clear advantage in near-term profit trajectory.
-17.40%
Negative equity/share CAGR over 10 years while 1177.HK stands at 484.74%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
29.23%
5Y equity/share CAGR above 1.5x 1177.HK's 10.77%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1.66%
Below 50% of 1177.HK's 25.53%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
No Data
No Data available this quarter, please select a different quarter.
7.22%
Inventory growth of 7.22% while 1177.HK is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
-10.57%
Negative asset growth while 1177.HK invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.71%
We have a declining book value while 1177.HK shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.67%
We’re deleveraging while 1177.HK stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-90.19%
We cut SG&A while 1177.HK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.